- €445.36m
- €510.81m
- €65.43m
Brief: Genfit Reports Full-Year 2022 Financial Results And Provides Corporate Update
Brief: Genfit Says Revenues For 2022 Eur 20.2 Mln vs Eur 80.1 Mln
Brief: Genfit Reports Third Quarter 2022 Financial Information
Brief: Genfit H1 Net Loss At EUR 10 Mln
Brief: Biopharma company GENFIT agrees to buy Swiss company Versantis
Brief: FDA Grants Genfit’s GNS561 Orphan Drug Designation
U.S. STOCKS ON THE MOVE-Kohl's Corp, Target Corp, Veru Inc
Brief: Genfit Reports Q1 Revenues Amounted To EUR 3.895 Million
Brief: GENFIT FY Net Result Turns To Profit Of EUR 67.3 Million
Genfit rises as cash position benefits from Ipsen deal
Brief: Genfit FY Revenue Up At EUR 80.1 Mln
Refinitiv Newscasts - UK Day Ahead: Tech slide, Omicron worries pull shares lower; UK, US data in view
Tech slide, Omicron worries pull European shares lower (updated)
Ipsen deal puts Genfit on track for best day in almost 10 yrs
Genfit heads for best day in almost 10 yrs on Ipsen deal
Brief: Genfit Acquires Rights To Novel Asset From Genoscience Pharma
Brief: Ipsen, Genfit Sign Exclusive Licensing Agreement For Elafibranor
Genfit shares rise on NSI4 tech stage 1 study results
Brief: Genfit Says NIS4 Identifies Patients With 'At-Risk' NASH